Skip to main content

Table 3 Relationship between serum concentration of biomarkers at baseline and disease progression at week 52

From: Serum surfactant protein D as a predictive biomarker for the efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis: a post-hoc analysis of the phase 3 trial in Japan

Biomarker Concentration at baseline Treatment Disease progression at week 52 p-value
Yes No
SP-D Low Pirfenidone 15 (19.2%) 63 (80.8%) 0.0949
Placebo 17 (33.3%) 34 (66.7%)
High Pirfenidone 26 (32.5%) 54 (67.5%) 0.3605
Placebo 21 (40.4%) 31 (59.6%)
SP-A Low Pirfenidone 23 (28.0%) 59 (72.0%) 0.4394
Placebo 17 (34.7%) 32 (65.3%)
High Pirfenidone 18 (23.7%) 58 (76.3%) 0.0807
Placebo 21 (38.9%) 33 (61.1%)
KL-6 Low Pirfenidone 19 (26.0%) 54 (74.0%) 0.2430
Placebo 20 (37.0%) 34 (63.0%)
High Pirfenidone 22 (25.9%) 63 (74.1%) 0.2397
Placebo 18 (36.7%) 31 (63.3%)
  1. All patients were dichotomized by the median concentration of each biomarker at baseline to the high and low biomarker subgroups. The disease progression was defined by a > 10% relative decline in vital capacity from baseline and/or death. Fisher's exact test
  2. SP surfactant protein, KL Krebs von den Lungen